Clinical Implementation of Genomic Medicine in Primary Care
作者： Alex H. Cho , Lori A. Orlando
DOI: 10.1016/B978-0-12-382227-7.00025-2
关键词:
摘要: Genomics has the potential to enhance healthcare provided in primary care through several mechanisms: tailoring prevention, raising provider awareness, increasing patient engagement, and selecting optimal therapy. This chapter outlines these benefits discusses existing barriers its integration clinical environment, which can be categorized into patient-level, provider-level, health-system-level factors. It concludes with a case study of type 2 diabetes genetic risk testing.
sci-hub.se 参考文章(69)
To know or not to know? Not the only question in familial breast cancer risk communication Ecancermedicalscience. ,vol. 5, pp. 239- 239 ,(2011) , 10.3332/ECANCER.2011.239
C E Lewis, Disease prevention and health promotion practices of primary care physicians in the United States. American Journal of Preventive Medicine. ,vol. 4, pp. 9- 16 ,(1988)
Parminder Raina, Judith Allanson, Pasqualina Santaguida, June Carroll, Brenda Wilson, Julian Little, Homa Keshavarz, Nadeem Qureshi, Clinical utility of cancer family history collection in primary care. Evidence Report/Technology Assessment. pp. 1- 94 ,(2009)
TE Klein, RB Altman, Niclas Eriksson, BF Gage, SE Kimmel, MT Lee, NA Limdi, D Page, DM Roden, MJ Wagner, MD Caldwell, JA Johnson, YT Chen, MS Wen, Y Caraco, I Achache, S Blotnick, M Muszkat, JG Shin, HS Kim, G Suarez-Kurtz, JA Perini, E Silva-Assuncao, JL Anderson, BD Horne, JF Carlquist, RL Berg, JK Burmester, BC Goh, SC Lee, F Kamali, E Sconce, AK Daly, AH Wu, TY Langaee, H Feng, L Cavallari, K Momary, M Pirmohamed, A Jorgensen, CH Toh, P Williamson, H McLeod, JP Evans, KE Weck, C Brensinger, Y Nakamura, T Mushiroda, D Veenstra, L Meckley, MJ Rieder, AE Rettie, M Wadelius, H Melhus, CM Stein, U Schwartz, D Kurnik, E Deych, P Lenzini, C Eby, LY Chen, P Deloukas, A Motsinger-Reif, H Sagreiya, BS Srinivasan, E Lantz, T Chang, M Ritchie, LS Lu, Estimation of the warfarin dose with clinical and pharmacogenetic data The New England Journal of Medicine. ,vol. 360, pp. 753- 764 ,(2009) , 10.1056/NEJMOA0809329
D. G Altman, J M. Bland, Absence of evidence is not evidence of absence BMJ. ,vol. 311, pp. 485- 485 ,(1995) , 10.1136/BMJ.311.7003.485
SLCO1B1 variants and statin-induced myopathy--a genomewide study The New England Journal of Medicine. ,vol. 359, pp. 789- 799 ,(2008) , 10.1056/NEJMOA0801936
R. E. Aubert, E. J. Stanek, J. Yao, J. R. Teagarden, M. Subar, R. S. Epstein, T. C. Skaar, Z. Desta, D. A. Flockhart, Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors Journal of Clinical Oncology. ,vol. 27, ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.CRA508
Shilpa Grover, Sapna Syngal, Genetic testing in gastroenterology: Lynch syndrome Best Practice & Research Clinical Gastroenterology. ,vol. 23, pp. 185- 196 ,(2009) , 10.1016/J.BPG.2009.02.006
J. O’Daniel, J. Lucas, P. Deverka, D. Ermentrout, G. Silvey, D.F. Lobach, S.B. Haga, Factors influencing uptake of pharmacogenetic testing in a diverse patient population. Public Health Genomics. ,vol. 13, pp. 48- 54 ,(2010) , 10.1159/000217795
Kathy L. Hudson, M.K. Holohan, Francis S. Collins, Keeping Pace with the Times — The Genetic Information Nondiscrimination Act of 2008 The New England Journal of Medicine. ,vol. 358, pp. 2661- 2663 ,(2008) , 10.1056/NEJMP0803964